LivaNova PLC ( (LIVN) ) has released its Q1 earnings. Here is a breakdown of the information LivaNova PLC presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
LivaNova PLC is a global medical technology company specializing in innovative solutions for neurological and cardiac conditions, with a strong presence in over 100 countries. In its first-quarter 2025 earnings report, LivaNova announced a significant revenue increase and updated its full-year guidance to reflect recent developments. The company reported a 7.4% increase in revenue on a reported basis, with a 10.4% organic growth, driven by strong performance in cardiopulmonary and neuromodulation segments. Despite a GAAP loss per share due to environmental liabilities, the adjusted earnings per share showed improvement. LivaNova also highlighted its progress in regulatory and clinical milestones, particularly in its obstructive sleep apnea program. Looking forward, LivaNova has raised its revenue growth expectations for 2025, indicating confidence in its operational performance and strategic initiatives.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue